CRISPR Therapeutics AG - NAMEN AKT (CRSP)

Historical Portfolio Holders from Q4 2016 to Q1 2024

All holders as of March 31, 2024
Q1 2024
Type / Class
Equity / NAMEN AKT
Shares, excl. options Q1 2024
55.4 M
Holdings value Q1 2024
$3.78 B
Value change Q1 2024
+$140 M
Grand Portfolio weight change Q1 2024
+0%
Number of holders
451
Number of buys Q1 2024
211
Number of sells Q1 2024
-189
Average buys Q1 2024 %
+0.006%
Average sells Q1 2024 %
-0.002%
CUSIP
H17182108
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q1 55.4 M $3.78 B +$140 M $68.16 451
2023 Q4 55.1 M $3.45 B +$76.5 M $62.60 467
2023 Q3 53.7 M $2.44 B -$2.32 M $45.39 396
2023 Q2 53.9 M $3.02 B -$106 M $56.14 405
2023 Q1 56 M $2.53 B +$37.9 M $45.23 367
2022 Q4 55.3 M $2.25 B -$39.6 M $40.65 380
2022 Q3 53.6 M $3.5 B -$158 M $65.35 402
2022 Q2 54.9 M $3.3 B +$273 M $60.77 399
2022 Q1 48.6 M $3.05 B +$484 M $62.77 404
2021 Q4 41.8 M $3.17 B +$68.8 M $75.78 413
2021 Q3 39.3 M $4.39 B -$50.8 M $111.93 454
2021 Q2 40.6 M $6.56 B -$213 M $161.89 490
2021 Q1 42.6 M $5.19 B -$577 M $121.85 429
2020 Q4 47.1 M $7.21 B +$34.7 M $153.11 388
2020 Q3 47.8 M $4 B +$725 M $83.64 296
2020 Q2 37.5 M $2.75 B +$288 M $73.49 260
2020 Q1 35.3 M $1.5 B +$147 M $42.41 240
2019 Q4 31.5 M $1.92 B +$255 M $60.90 241
2019 Q3 27.4 M $1.12 B -$8.94 M $40.99 174
2019 Q2 27.3 M $1.28 B +$105 M $47.10 179
2019 Q1 25.9 M $926 M +$146 M $35.72 163
2018 Q4 22.1 M $631 M -$52.6 M $28.57 151
2018 Q3 22.8 M $1.01 B +$171 M $44.35 171
2018 Q2 18.1 M $1.06 B +$2.99 M $58.76 171
2018 Q1 18.7 M $855 M +$304 M $45.71 131
2017 Q4 12.5 M $293 M +$61.8 M $23.48 82
2017 Q3 10 M $179 M +$6.2 M $17.87 58
2017 Q2 9.68 M $155 M -$3.83 M $16.02 33
2017 Q1 9.69 M $210 M -$3.15 M $21.76 34
2016 Q4 9.83 M $198 M +$198 M $20.26 26